CHAT Protein

CHAT Protein

<div class="infobox infobox-protein">

| Property | Value |
|----------|-------|
| Protein Name | Choline Acetyltransferase |
| Gene | CHAT |
| UniProt ID | P21908 |
| Molecular Weight | ~82 kDa (human) |
| Subcellular Localization | Cytoplasm of cholinergic neurons |
| Protein Family | Carnitine/choline acetyltransferase family |
| Tissue Expression | Cholinergic neurons (brain, spinal cord, periphery) |

</div>

Overview

Choline acetyltransferase (CHAT) is the enzyme that synthesizes the neurotransmitter acetylcholine (ACh) from choline and acetyl-CoA[@misawa2011]. It is the definitive marker for cholinergic neurons—cells that use acetylcholine as their primary neurotransmitter. CHAT is essential for cholinergic signaling throughout the nervous system, including in brain regions critical for memory and attention (basal forebrain), motor control (brainstem and spinal cord), and autonomic function.

The cholinergic system is prominently affected in Alzheimer's disease, where CHAT activity is dramatically reduced in the basal forebrain and cortex. This loss underlies the cognitive deficits characteristic of AD and has driven the development of cholinesterase inhibitor drugs (donepezil, rivastigmine, galantamine) as symptomatic treatments[@obrien2023].

Structure and Function

Protein Structure

CHAT has a characteristic enzyme architecture[@misawa2011]:

CHAT Protein

<div class="infobox infobox-protein">

| Property | Value |
|----------|-------|
| Protein Name | Choline Acetyltransferase |
| Gene | CHAT |
| UniProt ID | P21908 |
| Molecular Weight | ~82 kDa (human) |
| Subcellular Localization | Cytoplasm of cholinergic neurons |
| Protein Family | Carnitine/choline acetyltransferase family |
| Tissue Expression | Cholinergic neurons (brain, spinal cord, periphery) |

</div>

Overview

Choline acetyltransferase (CHAT) is the enzyme that synthesizes the neurotransmitter acetylcholine (ACh) from choline and acetyl-CoA[@misawa2011]. It is the definitive marker for cholinergic neurons—cells that use acetylcholine as their primary neurotransmitter. CHAT is essential for cholinergic signaling throughout the nervous system, including in brain regions critical for memory and attention (basal forebrain), motor control (brainstem and spinal cord), and autonomic function.

The cholinergic system is prominently affected in Alzheimer's disease, where CHAT activity is dramatically reduced in the basal forebrain and cortex. This loss underlies the cognitive deficits characteristic of AD and has driven the development of cholinesterase inhibitor drugs (donepezil, rivastigmine, galantamine) as symptomatic treatments[@obrien2023].

Structure and Function

Protein Structure

CHAT has a characteristic enzyme architecture[@misawa2011]:

The enzyme is organized as a homodimer, with each subunit containing distinct substrate-binding sites for choline and acetyl-CoA.

Catalytic Mechanism

CHAT catalyzes a simple transfer reaction:

Choline + Acetyl-CoA → Acetylcholine + CoA

The reaction proceeds through a ternary complex mechanism:

Regulation

CHAT activity is regulated at multiple levels:

| Regulatory Mechanism | Effect |
|---------------------|--------|
| Transcriptional control | Cell-type specific expression |
| Alternative splicing | Multiple isoforms with different properties |
| Post-translational modification | Phosphorylation affects activity |
| Product inhibition | Acetylcholine feedback |

Normal Biological Function

Acetylcholine Synthesis

CHAT is the sole enzyme for ACh biosynthesis:

Cholinergic Neurons

CHAT defines the cholinergic system:

Regional Specialization

Different CHAT isoforms are expressed in:

• Brain: Neuronal isoforms with high catalytic efficiency
• Muscle: Alternative splicing generates tissue-specific forms

Role in Neurodegeneration

Alzheimer's Disease

CHAT loss is a hallmark of AD pathophysiology[@obrien2023]:

Cholinergic Degeneration:

• Basal forebrain cholinergic neurons degenerate early
• CHAT activity reduced by 60-90% in AD cortex
• Loss correlates with cognitive deficits

• Amyloid pathology directly damages cholinergic neurons
• Tau pathology in basal forebrain
• Neuroinflammation contributes to neuron loss

• CHAT activity in CSF may reflect cholinergic integrity
• PET ligands for cholinergic terminals in development

Parkinson's Disease

CHAT alterations in PD include:

Other Conditions

| Disorder | CHAT Involvement |
|----------|------------------|
| DLB | Severe cholinergic loss |
| MCI | Early cholinergic changes |
| Myasthenia gravis | Autoantibodies affect function |
| ALS | Motor neuron cholinergic changes |

Therapeutic Implications

Current Treatments

Cholinesterase inhibitors are standard AD therapy[@hampel2018]:

| Drug | Mechanism | Status |
|------|-----------|--------|
| Donepezil | AChE inhibition | Approved |
| Rivastigmine | AChE/BChE inhibition | Approved |
| Galantamine | AChE modulation | Approved |

These drugs increase synaptic acetylcholine by inhibiting its breakdown, partially compensating for CHAT loss.

Emerging Strategies

| Strategy | Approach | Status |
|----------|----------|--------|
| CHAT gene therapy | Restore CHAT expression | Preclinical |
| Acetylcholine receptor agonists | Direct receptor activation | Various |
| Neurotrophic factors | Support cholinergic neurons | Research |

Biomarker Potential

CHAT-related biomarkers:

• CSF CHAT activity: May reflect cholinergic neuron health
• Imaging: Cholinergic terminal density markers

Key Publications

Cross-References

• [CHAT Gene](/genes/chat) — Gene encoding CHAT
• [Acetylcholine](/entities/acetylcholine) — The neurotransmitter
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Primary disease
• [Parkinson's Disease](/diseases/parkinsons-disease) — Related disease
• [Cholinergic System](/topics/cholinergic-system) — Neural system

See Also

• [Basal Forebrain](/brain-regions/basal-forebrain)
• [Acetylcholinesterase](/topics/acetylcholinesterase)
• [Cholinesterase Inhibitors](/topics/cholinesterase-inhibitors)

References

hampel2018, Cholinergic system: emerging targets for AD therapy (2018)
misawa2011, Choline acetyltransferase and acetylcholine (2011)
obrien2023, Cholinergic neurons in AD and cholinergic therapies (2023)